Gastric Carcinoma Marker Antibody (BY-1): sc-73568

Gastric Carcinoma Marker Antibody (BY-1) is a mouse monoclonal IgG1 antibody that detects Gastric Carcinoma Marker in human samples through enzyme-linked immunosorbent assay (ELISA). Anti-Gastric Carcinoma Marker antibody (BY-1) plays a crucial role in the diagnosis and monitoring of gastric carcinoma, a malignancy that can arise in various regions of the stomach and has the potential to metastasize to adjacent organs and lymph nodes. Gastric Carcinoma Marker (BY-1) antibody targets proteins primarily located in the cytoplasm of gastric epithelial cells, where these proteins are involved in cellular signaling pathways that regulate cell proliferation and apoptosis. Understanding Gastric Carcinoma Marker localization is vital, as this knowledge can provide insights into the mechanisms of tumorigenesis and the progression of gastric cancer. Gastric Carcinoma Marker expression in gastric carcinoma cells can also aid in distinguishing between the two major types of gastric carcinoma: intestinal type adenocarcinoma and diffuse type adenocarcinoma, which exhibit distinct histological features. Using Gastric Carcinoma Marker (BY-1) monoclonal antibody in research and clinical settings helps scientists and healthcare professionals enhance their understanding of gastric cancer biology and improve diagnostic accuracy, ultimately leading to better patient management and treatment strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Gastric Carcinoma Marker Antibody (BY-1) References:

1. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.  |  Hammarström, S. 1999. Semin Cancer Biol. 9: 67-81. PMID: 10202129
2. Stromal CEA immunoreactivity is correlated with lymphatic invasion of human esophageal carcinoma.  |  Kijima, H., et al. 2000. Int J Oncol. 16: 677-82. PMID: 10717234
3. Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation.  |  Ilantzis, C., et al. 2002. Neoplasia. 4: 151-63. PMID: 11896570
4. Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo.  |  Biglari, A., et al. 2006. Gene Ther. 13: 602-10. PMID: 16397508
5. Detection of CEA in human serum using surface-enhanced Raman spectroscopy coupled with antibody-modified Au and γ-Fe₂O₃@Au nanoparticles.  |  Lin, Y., et al. 2016. J Pharm Biomed Anal. 121: 135-140. PMID: 26808062
6. Carcinoembryonic Antigen (CEA) and Hepatic Metastasis in Colorectal Cancer: Update on Biomarker for Clinical and Biotechnological Approaches.  |  Campos-da-Paz, M., et al. 2018. Recent Pat Biotechnol. 12: 269-279. PMID: 30062978
7. Aptamer-based biosensor for detecting carcinoembryonic antigen.  |  Xiang, W., et al. 2020. Talanta. 214: 120716. PMID: 32278406
8. MXD4/MAD4 Regulates Human Keratinocyte Precursor Fate.  |  Coutier, J., et al. 2023. J Invest Dermatol. 143: 105-114.e12. PMID: 36007550
9. Dual-Channel Detection of Breast Cancer Biomarkers CA15-3 and CEA in Human Serum Using Dialysis-Silicon Nanowire Field Effect Transistor.  |  Li, H., et al. 2022. Int J Nanomedicine. 17: 6289-6299. PMID: 36536938
10. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.  |  Tsang, KY., et al. 1995. J Natl Cancer Inst. 87: 982-90. PMID: 7629885